Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
IPO Year: 2018
Exchange: NASDAQ
Website: tricida.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/13/2022 | $25.00 | Buy | Goldman |
| 11/16/2021 | $7.00 | Underweight → Neutral | JP Morgan |
Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today that Dr. Sandra Coufal, M.D. will join Toragen as its new CEO. Dr. Coufal brings over 30 years of experience to Toragen as a physician and serial entrepreneur working with multiple successful companies in medicine, chemistry, biotechnology, material sciences, and digital technology. This press release features multimedia. View the full release here: https://www.businesswire.c
Goldman initiated coverage of Tricida with a rating of Buy and set a new price target of $25.00
JP Morgan upgraded Tricida from Underweight to Neutral and set a new price target of $7.00
SC 13G/A - Tricida, Inc. (0001595585) (Subject)
SC 13G/A - Tricida, Inc. (0001595585) (Subject)
SC 13G/A - Tricida, Inc. (0001595585) (Subject)
SC 13G/A - Tricida, Inc. (0001595585) (Subject)
SC 13D/A - Tricida, Inc. (0001595585) (Subject)
SC 13D/A - Tricida, Inc. (0001595585) (Subject)
SC 13G/A - Tricida, Inc. (0001595585) (Subject)
SC 13G - Tricida, Inc. (0001595585) (Subject)
SC 13D/A - Tricida, Inc. (0001595585) (Subject)
SC 13G/A - Tricida, Inc. (0001595585) (Subject)
EFFECT - Tricida, Inc. (0001595585) (Filer)
15-12G - Tricida, Inc. (0001595585) (Filer)
S-8 POS - Tricida, Inc. (0001595585) (Filer)
POSASR - Tricida, Inc. (0001595585) (Filer)
POS AM - Tricida, Inc. (0001595585) (Filer)
8-K - Tricida, Inc. (0001595585) (Filer)
8-K - Tricida, Inc. (0001595585) (Filer)
8-K - Tricida, Inc. (0001595585) (Filer)
8-K - Tricida, Inc. (0001595585) (Filer)
8-K - Tricida, Inc. (0001595585) (Filer)
Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in October the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration
Tricida, Inc. (NASDAQ:TCDA), announced today that the Board of Directors has authorized Tricida to initiate a review of strategic alternatives to maximize stakeholder value. To facilitate this review, Tricida has engaged Stifel and its wholly owned affiliate, Miller Buckfire, to serve as investment banking advisors and SierraConstellation Partners LLC to serve as a financial advisor. This strategic review may include consideration of the sale of the Company and/or its assets. Tricida is also currently evaluating plans to reduce operating expenses and anticipates initiating and announcing these plans in November 2022. The Board of Directors and Tricida intend to conduct a thorough review of
Webcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). Primary Endpoint Analysis The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 pla
Tricida, Inc. (NASDAQ:TCDA) announced today that it has entered into a debt facility with Hercules Capital, Inc. (NYSE:HTGC), a leader in customizing debt financing for companies in the life sciences and technology-related markets. The total amount of the debt facility is $125 million of which $100 million will be available for drawdown at Tricida's option subject to the achievement of certain milestones. "As we prepare to report the topline results from the VALOR-CKD renal outcomes trial this month, we want to ensure we are positioned both financially and strategically to move toward a potential NDA resubmission, potential FDA approval and subsequent commercialization of veverimer," said
Tricida, Inc. (NASDAQ:TCDA) announced today that a late-breaking clinical trial abstract on the Phase 3, VALOR-CKD renal outcomes trial has been selected by the American Society of Nephrology (ASN) and the Kidney Week Education Committee for oral presentation in the High-Impact Clinical Trials session at the ASN Kidney Week 2022 meeting that is currently scheduled to take place November 3 to 6, 2022 in Orlando, Florida. The presentation entitled "VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients With Metabolic Acidosis" will be given by Dr. Navdeep Tangri, M.D., Ph.D., F.R.C.P.(C), Professor of Medicin
Tricida, Inc. (NASDAQ:TCDA) today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company's key initiatives. The presentation will be accessible on the Tricida website at IR.Tricida.com on Monday, September 12, 2022 at 4:30 pm PT / 1:30 pm ET. An archive of the presentation will be available for 90 days following the presentation. About Tricida Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow CKD progression in pat
Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and six months ended June 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in May 2022 that it stopped its VALOR-CKD renal outcomes trial early for administrative reasons as permitted by the existing study protocol to allow for six months of financial runway following the reporting of top-line results, which is anticipated to occur in October 2022. The VALOR-CKD trial has continued to accrue primary endpoint events as clinical trial subjects complete their participation in the study which, for the last subject, is currently projected to
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022. Tricida will host a webcast and conference call at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows: Tricida Second Quarter Financial Results Conference CallMonday, August 8, 20224:30 pm Eastern Time Webcast:IR.Tricida.com Dial-in:(800) 715-9871 International:(646) 307-1963 Conference ID:3576787 A replay of the webcast will be available on Tricida's website approximately two hours
SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) announced today that as anticipated it is stopping its VALOR-CKD renal outcomes trial early for administrative reasons pursuant to the existing study protocol to allow for six months of financial runway following the reporting of top-line results, currently anticipated to occur early in the fourth quarter of 2022. As of May 18, 2022, the average treatment duration of the 1480 subjects randomized in the trial was approximately 25 months, and the trial had accrued 237 subjects with positively adjudicated primary endpoint events, defined as renal death, end-stage renal disease (ESRD), or greater than
SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three months ended March 31, 2022 and provided an update on key initiatives. Business Update Tricida continued to execute on the conduct of the VALOR-CKD renal outcomes clinical trial. Enrollment of patients in the VALOR-CKD trial was completed at the end of 2021 with 1,480 subjects randomized. As of May 9, 2022, randomized subjects had an average treatment duration of approximately 25 months, and the trial had accrued 233 subjects with positively adjudicated primary endpoint events, defined as renal death, end-stage renal disease (ESRD), or greater than or
4 - Tricida, Inc. (0001595585) (Issuer)
4 - Tricida, Inc. (0001595585) (Issuer)
4 - Tricida, Inc. (0001595585) (Issuer)
4 - Tricida, Inc. (0001595585) (Issuer)
4 - Tricida, Inc. (0001595585) (Issuer)
4 - Tricida, Inc. (0001595585) (Issuer)
4 - Tricida, Inc. (0001595585) (Issuer)
4 - Tricida, Inc. (0001595585) (Issuer)
4 - Tricida, Inc. (0001595585) (Issuer)
4 - Tricida, Inc. (0001595585) (Issuer)
Webcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). Primary Endpoint Analysis The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 pla
Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and six months ended June 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in May 2022 that it stopped its VALOR-CKD renal outcomes trial early for administrative reasons as permitted by the existing study protocol to allow for six months of financial runway following the reporting of top-line results, which is anticipated to occur in October 2022. The VALOR-CKD trial has continued to accrue primary endpoint events as clinical trial subjects complete their participation in the study which, for the last subject, is currently projected to
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022. Tricida will host a webcast and conference call at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows: Tricida Second Quarter Financial Results Conference CallMonday, August 8, 20224:30 pm Eastern Time Webcast:IR.Tricida.com Dial-in:(800) 715-9871 International:(646) 307-1963 Conference ID:3576787 A replay of the webcast will be available on Tricida's website approximately two hours
SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three months ended March 31, 2022 and provided an update on key initiatives. Business Update Tricida continued to execute on the conduct of the VALOR-CKD renal outcomes clinical trial. Enrollment of patients in the VALOR-CKD trial was completed at the end of 2021 with 1,480 subjects randomized. As of May 9, 2022, randomized subjects had an average treatment duration of approximately 25 months, and the trial had accrued 233 subjects with positively adjudicated primary endpoint events, defined as renal death, end-stage renal disease (ESRD), or greater than or
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its first quarter 2022 financial results after the close of market on Tuesday, May 10, 2022. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its first quarter financial results and business progress. The call or webcast may be accessed as follows: Tricida Conference Call Information Tricida will host its First Quarter Financial Results and Business Update Conference Call and webcast on Tuesday, May 10, 2022, at 4:30 pm Eastern Time. The call or webcast may be accessed as follows: Tricida Conference CallTuesday, May 10, 20224:30 p
Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three months and year ended December 31, 2021 and provided an update on key initiatives. Business Update Tricida continued to execute on the conduct of the VALOR-CKD renal outcomes clinical trial. Enrollment of patients in the VALOR-CKD trial was completed at the end of 2021 with 1,480 subjects randomized. As of March 28, 2022, randomized subjects had an average treatment duration of approximately 24 months, and the trial had accrued 217 subjects with positively adjudicated primary endpoint events, defined as renal de
SOUTH SAN FRANCISCO, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its fourth quarter and year-end 2021 financial results after the close of market on Tuesday, March 29, 2022. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its fourth quarter financial results and business progress. The call or webcast may be accessed as follows: Tricida Conference Call Information Tricida will host its Fourth Quarter Financial Results and Business Update Conference Call and webcast on Tuesday, March 29, 2022, at 4:30 pm Eastern Time. The webcast or conference call may be accessed as follows: Tricida Fourth Q
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD, announced today financial results for the three and nine months ended September 30, 2021 and provided an update on key initiatives. Update on Key Initiatives: Tricida continued to execute on recruitment and conduct of the VALOR-CKD renal outcomes clinical trial. As of November 5, 2021, the trial has randomized over 1,470 of its pla
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its third quarter 2021 financial results after the close of market on Monday, November 8, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its third quarter financial results and business progress. The webcast or call may be accessed as follows: Tricida Conference Call Information Tricida will host its Third Quarter Financial Results and Business Update Conference Call and webcast on Monday November 8, 2021 at 4:30 pm Eastern Time. The webcast or conference call may be accessed as follows: Tricida Conference Call
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD, announced today financial results for the three and six months ended June 30, 2021 and provided an update on key initiatives. Recent Events Tricida continues to execute on recruitment and conduct of the VALOR-CKD renal outcomes clinical trial. As of August 6, 2021, the VALOR-CKD trial had randomized 1,455 of the planned 1,600 subje
Gainers Jaguar Health (NASDAQ:JAGX) stock rose 6215.8% to $5.35 during Monday's regular session. The current volume of 532.2K shares is 6.8% of Jaguar Health's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $808.9 million. Intelligent Bio Solutions (NASDAQ:INBS) stock increased by 424.84% to $1.38. As of 12:30 EST, Intelligent Bio Solutions's stock is trading at a volume of 115.7 million, which is 206846.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $25.2 million. Pliant Therapeutics (NASDAQ:PLRX) stock rose 46.3% to $32.93. Trading volume for this
On Monday, 12 stocks hit new 52-week lows. Noteable 52-Week Lows: Innovative Ind Props (NYSE:IIPR) was the largest, in terms of market cap, to set a new 52-week low. Tricida (NASDAQ:TCDA) was the smallest company by market cap to set a new 52-week low. Amesite (NASDAQ:AMST) saw the most pronounced move, as shares traded down 17.22% to hit its new 52-week low. Clough Global Equity (AMEX:GLQ) shares actually gained 0.16%, rebounding after it reached its 52-week low. Stocks dropping to new 52-week lows on Monday: Innovative Ind Props (NYSE:IIPR) stock broke to a new 52-week low of $87.20 on Monday. Shares of the company traded up 0.92%. Pacira BioSciences (NASDAQ:PCRX) shares ma
Friday saw 23 companies set new 52-week lows. Significant Points From Today's 52-Week Lows: L3Harris Technologies (NYSE:LHX) was the largest firm by market cap to set a new 52-week low. The smallest company on a market cap basis to set a new 52-week low was Digital Brands Group (NASDAQ:DBGI). Windtree Therapeutics (NASDAQ:WINT) saw the most pronounced move, as shares traded down 26.62% to hit its new 52-week low. Arqit Quantum (NASDAQ:ARQQ) saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low. Stocks that set new 52-week lows on Friday are as follows: L3Harris Technologies (NYSE:LHX) stock set a new 52-week low of $190.11 on Frid
Gainers Apexigen (NASDAQ:APGN) shares moved upwards by 39.7% to $2.5 during Thursday's pre-market session. The company's market cap stands at $56.4 million. Hyperfine (NASDAQ:HYPR) shares increased by 14.75% to $1.01. The company's market cap stands at $71.2 million. Tricida (NASDAQ:TCDA) stock rose 13.2% to $0.16. The company's market cap stands at $9.0 million. Sonnet BioTherapeutics (NASDAQ:SONN) shares increased by 11.91% to $1.41. The company's market cap stands at $11.1 million. Zymeworks BC (NASDAQ:ZYME) stock moved upwards by 11.5% to $11.15. The market value of their outstanding shares is at $702.4 million. RenovoRx (NASDAQ:RNXT) stock rose 9.58% to $4.0. The company's market
Gainers Tricida, Inc. (NASDAQ:TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday. Huadi International Group Co., Ltd. (NASDAQ:HUDI) rose 26.7% to $7.16 in pre-market trading after gaining over 3% on Wednesday. Starbox Group Holdings Ltd. (NASDAQ:STBX) shares rose 22.1% to $3.65 in pre-market trading after the company reported a rise in FY22 earnings. AIM ImmunoTech Inc. (NYSE:AIM) shares rose 15.8% to $0.73 in pre-market trading after dropping 18% on Wednesday. AIM ImmunoTech recently entered into a sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca. Zymeworks Inc. (NASDAQ:ZYME) rose 12% to $11.20 in pre-market trading. B
Gainers Ontrak, Inc. (NASDAQ:OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+ program members. Aceragen Inc. (NASDAQ:ACGN) shares gained 61.3% to $11.65. TC Biopharm (Holdings) Plc (NASDAQ:TCBP) gained 44% to $7.07 after the company on Tuesday announced a strategic collaboration to advance gamma-delta T cells in oncology. Energy Vault Holdings, Inc. (NYSE:NRGV) shares gained 42.4% to $5.08 after the company updated Q4 and FY22 expected revenue results. G Medical Innovations Holdings Ltd (NASDAQ:GMVD) jumped 34.6% to $4.66. Sigilon Therapeutics, Inc. (NASDAQ:SGTX) cli
Gainers Ontrak (NASDAQ:OTRK) shares increased by 145.2% to $1.41 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 128.7 million shares, making up 47983.4% of its average full-day volume over the last 100 days. The company's market cap stands at $38.1 million. Ontrak (NASDAQ:OTRKP) shares moved upwards by 50.4% to $1.35. Trading volume for Ontrak's stock is 310.5K as of 12:30 EST. This is 1716.4% of its average full-day volume over the last 100 days. TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 37.11% to $6.76. As of 12:30 EST, TC BioPharm (Holdings)'s stock is trading at a volume of 21.3 million, which is 8237.3% of its average full-day volu
Gainers Ontrak (NASDAQ:OTRK) stock increased by 44.3% to $0.83 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.4 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 25.55% to $6.19. The market value of their outstanding shares is at $246.0 million. Tricida (NASDAQ:TCDA) stock moved upwards by 21.81% to $0.16. The market value of their outstanding shares is at $9.3 million. Avenue Therapeutics (NASDAQ:ATXI) stock increased by 18.59% to $2.36. The market value of their outstanding shares is at $11.2 million. Sigilon Therapeutics (NASDAQ:SGTX) shares moved upwards by 14.89% to $0.47. The market value of their outstanding shares
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. Tricida, Inc. (NASDAQ:TCDA) The company’s stock dropped around 98% over the past six months. The company’s stock has a 52-week low of $0.13 . RSI Value: 28.21
As previously disclosed, on December 7, 2022, Tricida, Inc. (“Tricida”) received notice from Patheon Austria GmbH & Co KG (“Patheon”) alleging that Tricida was in material breach of the Manufacturing and Commercial Supply Agreement, effective October 4, 2019 (as amended by amendment no. 1 dated March 30, 2021, amendment no. 2 dated August 26, 2021, amendment no. 3 dated July 1, 2022 and amendment no. 4 dated September 15, 2022, collectively the “Agreement”) between Tricida and Patheon. The notice also purported to terminate the Agreement and sought payment for additional amounts and damages that Patheon claims are now due to it under the Agreement and applicable law. On December 19, 2022, T